Heterogeneity in assays (isoform- and compartment-specific HSP measurements), outcome definitions, and imaging/biomarker panels limits cross-study comparability, while long-term safety of chronic HSP modulation, repeated thermal/photothermal exposure, and sustained HSP90 inhibition remains insufficiently characterized with respect to host defense, tumor surveillance, and tissue remodeling. Here, HSP90AB1 is linked to neoplasm.